Lormetazepam

Summary

Lormetazepam (CHEMBL22097) is an approved small-molecule sedative (ATC N05CD06); indicated across 5 conditions including anxiety and dementia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CD06
• Indications: 5 conditions
• Clinical trials: 4
• Chemistry: 335.2 Da · C16H12Cl2N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL22097
Name	Lormetazepam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	13314
ChEBI	CHEBI:52993
ATC	N05CD06
Molecular formula	C16H12Cl2N2O2
Molecular weight	335.2
InChIKey	FJIKWRGCXUCUIG-UHFFFAOYSA-N

SMILES: CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3Cl

IUPAC name: 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3H-1,4-benzodiazepin-2-one

ChEBI definition: A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.

Pharmacological roles (ChEBI): sedative.

Also known as: Chlorotemazepam, Loramet, Lormetazepam, Methyllorazepam, WY-4082, Lormetazepan, LORMETAZEPAM, lormetazepam

Patent coverage: 1,576 distinct patent families (6,421 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 6,394 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Alpha-2A adrenergic receptor, Muscarinic acetylcholine receptor M2, Kappa-type opioid receptor, 3’,5’-cyclic-AMP phosphodiesterase 4D, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	8.85	AC50	1.4	nM	CHEMBL_ACT_25130812
PDE4D	5.25	AC50	5600	nM	CHEMBL_ACT_25185546
OPRK1	5.09	AC50	8100	nM	CHEMBL_ACT_25129631

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
sleep disorder	3	MONDO:0100081	EFO:0008568

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02022592	PHASE4	COMPLETED	Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care
NCT00679900	PHASE3	COMPLETED	Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties
NCT00788515	PHASE3	TERMINATED	Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).